VivoSeq
Other

Metabolic Dysfunction-Associated Steatohepatitis

4

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Metabolic Dysfunction-associated Steatohepatitis is an early-stage landscape with 4 programs across 4 companies. The most active players are Boehringer Ingelheim, Boston Pharmaceuticals, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 1B

Boston Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2GSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Placebo Matching BI 3804379

Boehringer Ingelheim

Phase 23

Efimosfermin

Boston Pharmaceuticals

ECC4703

Eccogene

ECC0509

Eccogene

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSProtein / enzyme125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting3 · 100%

Clinical Trials

Trial Activity

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH
Recruiting·EEccogene·Phase 2·NCT07288138·160 enrolled
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Recruiting·GSK logoGSK·Phase 2·NCT06920043·42 enrolled
A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Subcutaneous Doses of BI 3804379 in Healthy Male and Female Participants and in Stable Patients With Advanced Fibrosis Due to MASH
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT06575400·124 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)